Beam Therapeutics' GAAP loss for 2021 was $370.638 million, up 90.5% from $194.592 million the previous year. Revenue increased multiple times to $51.844 million from $0.024 million a year earlier.
Beam Therapeutics' GAAP loss for 2021 was $370.638 million, up 90.5% from $194.592 million the previous year. Revenue increased multiple times to $51.844 million from $0.024 million a year earlier. 
investors.beamtx.com
English (US) 